Assembly Biosciences Announces Plenary Lecture at HEP DART 2019
December 06 2019 - 8:00AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced that Richard Colonno, PhD, Executive
Vice President and Chief Scientific Officer Virology, will present
a Plenary Lecture, “Eliminating Residual HBV Replication – A
Critical Gateway to Cure” at the HEP DART Meeting on Tuesday, Dec
10, 2019 at 5:30pm HST in Kauai, HI. The presentation will include
an in-depth review of interim long-term data from the ongoing Phase
2 study of ABI-H0731, Assembly’s lead core inhibitor, for the
treatment of chronic Hepatitis B infection, which were reported at
AASLD 2019 last month
.
Following the lecture, Dr. Colonno’s slides will be available on
the Events & Presentations page in the Investors section of the
company's website at assemblybio.com.
About Assembly Biosciences Assembly
Biosciences, Inc. is a clinical-stage biotechnology company
developing innovative therapeutics targeting hepatitis B virus
(HBV) and diseases associated with the microbiome. The HBV program
is focused on advancing a new class of potent, oral core inhibitors
that have the potential to increase cure rates for chronically
infected patients. The microbiome program is developing novel
oral live microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP-compliant banking and production,
and targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information,
visit assemblybio.com.
Contacts Assembly Biosciences, Inc. Investors:
Lauren Glaser (415) 521-3828lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Sep 2023 to Sep 2024